InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted immune therapies to expand specific CD8 T-cells in vivo, today presented new interim data ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over ...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week announced that the US Food and Drug Administration (FDA) granted ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

CAR T therapies have transformed treatment options for some blood cancers. They have also exposed one of cell therapy's ...

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...

Approximately 30%-50% of patients with relapsed or refractory B-cell non-Hodgkin lymphomas have achieved durable remissions with CAR T-cell therapies targeting CD19 over follow-up periods of up to 5 ...

Lymphoma-free survival exceeding 5 years in early recipients of the cellular therapy ...

Scientists at Florida International University may have found a way to make a powerful cancer treatment work even better. The treatment, called CAR-T therapy, uses a patient's own immune cells to ...

An earlier readout from the phase III TRIANGLE trial indicated that transplant-eligible patients with mantle cell lymphoma (MCL) have improved failure-free survival (FFS) outcomes with the addition of ...